MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL

Robert Sanchez,Khurram Nasir, Alexa Klimchak,Andreas Kuznik,Florence Joulain,Andrew Briggs

Journal of the American College of Cardiology（2017）

引用 0|浏览2

暂无评分

摘要

Background: Association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) events is well established. We aim to model one-year benefits of additional LDL-C lowering with alirocumab on CV risk.Methods: Data from MarketScan was used to estimate baseline CV risk and lipid

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要